Top

Gepubliceerd in:

2025 | OriginalPaper | Hoofdstuk

16. Tumoren van de long, mediastinum en pleura

Auteurs : E. A. Kastelijn, F. M. N. H. Schramel, J. G. J. V. Aerts, F. N. Hofman, C. A. Ambarus, S. M. G. van de Pol, H. Tekatli, L. Steinbusch

Gepubliceerd in: Leerboek oncologie – online voorpublicatie

Uitgeverij: BSL Media & Learning

Samenvatting

Wereldwijd is longkanker het meest voorkomende type van de solide tumoren met roken als belangrijkste oorzakelijke factor. Longkanker is een van de meest fatale vormen van kanker in de wereld. Het verkrijgen van weefsel voor het stellen van de diagnose en het verrichten van een mutatieanalyse en eiwitexpressie is van groot belang voor de keuze van de behandeling. Doelgerichte therapie en immunotherapie hebben de behandeling en prognose van de patiënten met longkanker aanzienlijk verbeterd en krijgen steeds vaker een grotere rol in de behandeling van longkanker.

vorige hoofdstuk De rol van radiotherapie bij de behandeling van kanker

volgende hoofdstuk Maligne tumoren van de weke delen

Aberle DR, Admans AB, Berg CD, et al. Reduced lungcancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.CrossRefPubMed

Antonio JS, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. N Engl J Med. 2017;377:1919–29.CrossRef

Chang JY, Mehrann RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): longterm resuls of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22:1448–57.CrossRefPubMedPubMedCentral

Felip E, Altorki N, Zhou C, et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann of Onc. 2023;34:907–19.CrossRef

Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973–85.CrossRefPubMedPubMedCentral

Iovoli AJ, Yu B, Jun Ma S, et al. Quality of life after stereotactic body radiation therapy or surgery for early-stage NSCLC: a systematic review. JTO. 2022;3:1–11.

Koning H De, Aalst C Van der, Haaf K Ten, et al. Effects of volume CT lung cancer screening: mortality results of the NELSON randomized-controlled population based trial. World Conference on Lung Cancer. J Thorac Oncol. 2018;13(10):S185.

Kuang Y, Pierce CM, Chamg CH, et al. Chemoradiation-induced pneumonitis in patients with uresectable stage III non-small cell lung cancer: a systematic literature reviwu and meta-analysis. Lung Cancer. 2022;174:174–85.CrossRefPubMed

Lu S, Kato T, Dong X, Ahn M-J, Quang L-V, Soparattanapaisarn N, et al. Osimertinib after chemoradiotherapy in stage III EGFR-Mutated NSCLC. N Engl J Med. 2024;391(7):585–97.CrossRefPubMed

Solomon GJ, Ahn JS, Dziadziuszko R, et al. Efficacy and safety of adjuvant alectinib versus chemotherapy in patient with early stage ALK+ non-small cell lung cancer. Ann of Onc. 2023;34:S1295.CrossRef

Tsuboi M, Herbst RS, John T, et al. Overall survival with osimerinib in resected EGFR mutated NSCLC. N Engl J Med. 2023;389:137–47.CrossRefPubMed

WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon (France): International Agency for Research on Cancer; 2021. (WHO classification of tumours series, 5th ed.; vol. 5). https://publications.iarc.fr/595.

Wakelee H, Libermann M, Kato T, et al. Perioperative pembrolizumab for early stage non-small-cell lung cancer. N Engl J Med. 2023;389:491–503.CrossRefPubMedPubMedCentral

Wu Y, Tsuboi M, He J, et al. Osimirtinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711–23.CrossRefPubMed

Antonio JS, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342–50.CrossRef

Chang JY, SenanS, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small lung cancer: a pooled analysis of two randomized trials. Lancet Oncol. 2015;16:630–7.

Van der Drift MA, Karim-Vos HE, Siesling S, et al. Progress in standard of care therapy and modes survival benefit in the treatment of non-small cell lungcancer patients in the Netherlands in the last 20 years. J Thorac Oncol. 2012;7:291–8.CrossRefPubMed

Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706.CrossRefPubMed

Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:694.CrossRefPubMed

Henschke CI, Yankelevitz DE, Libby DM, et al. Survival of patients with stage I lungcancer detected on CT-screening. N Engl J Med. 2006;355:1763–71.CrossRefPubMed

Jeene PM, De Vries KC, Van Nes JGH, et al. Survival after whole brain radiotherapy for brain metastases form lung cancer and breast cancer is poor in 63252 Dutch patients treated between 2000 and 2014. Acta Oncol. 2018;57:637–43.CrossRefPubMed

Landelijke Werkgroep Longtumoren. Landelijke richtlijn niet-kleincellig longcarcinoom. Landelijke richtlijn, Versie: 2.0.

Paesmans M, Berghmans T, Dusart M, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European lung cancer working party for the international association for the study of lung cancer staging project. J Thorac Oncol. 2010;5:612.CrossRefPubMed

Sculier JP, Chansky K, Crowley JJ, et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6^th edition of the TNM Classification of Malignant Tumors and the proposals for the 7th ed. J Thorac Oncol. 2008;3:457.

Sequist LV, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011;22:2616–24.CrossRefPubMedPubMedCentral

Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent non-small-cell lung cancer after complete pulmonary resection. Ann Thorax Surg. 2007;83:409.CrossRef

Travis WD, Asamura H, Bankier A, et al. The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eight edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11(8):1204–23.

Titel: Tumoren van de long, mediastinum en pleura
Auteurs: E. A. Kastelijn
F. M. N. H. Schramel
J. G. J. V. Aerts
F. N. Hofman
C. A. Ambarus
S. M. G. van de Pol
H. Tekatli
L. Steinbusch
Uitgeverij: BSL Media & Learning
Boek: Leerboek oncologie – online voorpublicatie
Print ISBN: 978-90-368-3113-0

Elektronisch ISBN: 978-90-368-3114-7

Copyright: 2025
DOI: https://doi.org/10.1007/978-90-368-3114-7_16

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen